Real-World Patterns on Tumor Mutation Burden Testing in a Pan-Tumor Population
Authors:
- 29 January 2021
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (15) , 1879-1887
Abstract
Background: There is limited real-world information on use of tumor mutational burden (TMB) testing and characteristics of patients receiving it. Materials & methods: Patients ≥18 years old and dia... Lay abstract There is limited real-world information on the use of tumor mutational burden (TMB) testing and the characteristics of patients who are receiving it. TMB is the total number of mutatio...Keywords
Funding Information
- Merck & Co., Inc.
This publication has 18 references indexed in Scilit:
- Characteristics of patients receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ.Journal of Clinical Oncology, 2019
- Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic DatabaseJAMA, 2019
- Tumor mutational load predicts survival after immunotherapy across multiple cancer typesNature Genetics, 2019
- Implementing TMB measurement in clinical practice: considerations on assay requirementsESMO Open, 2019
- Methods of measurement for tumor mutational burden in tumor tissueTranslational Lung Cancer Research, 2018
- Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and cliniciansTranslational Lung Cancer Research, 2018
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenNew England Journal of Medicine, 2018
- Barriers to tumor mutation burden (TMB) testing in NSCLC patients in the US and EU.Journal of Clinical Oncology, 2018
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenGenome Medicine, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016